Amgen Testing Whether Different Is Better In Obesity, With Data Due This Year
GIP Receptor Antagonism Versus Agonism On Trial
Amgen’s obesity drug MariTide will not have Phase II results until late 2024, but the company’s Q4 earnings call was dominated by questions seeking insight about the drug’s potential.
You may also be interested in...
The company increased its full-year guidance in anticipation of Horizon’s Q4 contribution and sales for the quarter jumped 20%, but even excluding those drugs product sales were up 5%.
Lilly reports better than 50% sequential sales growth for Mounjaro, while Zepbound’s early launch has brought in $176m. The company also unveiled positive Phase IIb data with tirzepatide in NASH.
The Danish group has seen the kind of profit growth that other companies can only dream of. But nothing lasts forever: its 2024 guidance looks rather more modest.